Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Palatin Technologies (PTN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 148,234
  • Shares Outstanding, K 203,060
  • Annual Sales, $ 67,130 K
  • Annual Income, $ 24,700 K
  • 36-Month Beta 1.71
  • Price/Sales 2.32
  • Price/Cash Flow 6.15
  • Price/Book 6.15
  • Price/Earnings ttm 19.17
  • Earnings Per Share ttm 0.04
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/13/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.02
  • Number of Estimates 1
  • High Estimate -0.02
  • Low Estimate -0.02
  • Prior Year 0.01
  • Growth Rate Est. (year over year) -300.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.68 +5.88%
on 11/27/18
0.86 -16.28%
on 12/04/18
-0.11 (-13.25%)
since 11/14/18
3-Month
0.68 +5.88%
on 11/27/18
1.07 -32.71%
on 09/18/18
-0.29 (-28.71%)
since 09/14/18
52-Week
0.68 +5.88%
on 11/27/18
1.59 -54.72%
on 04/10/18
-0.12 (-14.29%)
since 12/14/17

Most Recent Stories

More News
Market Trends Toward New Normal in Palatin Technologies, Revance Therapeutics, Geo Group, QUANTENNA COMMS, The Navigators Group, and INVESCO MORTGAGE CAPITAL INC -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Palatin Technologies, Inc....

GEO : 22.48 (-1.40%)
QTNA : 14.86 (+0.34%)
NAVG : 69.51 (unch)
IVR : 15.73 (+0.64%)
PTN : 0.72 (-1.37%)
RVNC : 19.91 (-3.82%)
Palatin Technologies, Inc. Reports First Fiscal Quarter 2019 Results and Provides Corporate Update

Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic...

PTN : 0.72 (-1.37%)
Palatin Technologies, Inc. Announces First-in-Human Study Results of Subcutaneous Administration of PL-8177, An Investigational Melanocortin Receptor 1 Agonist

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need...

PTN : 0.72 (-1.37%)
Earnings Preview: Palatin (PTN) Q1 Earnings Expected to Decline

Palatin (PTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PTN : 0.72 (-1.37%)
Recent Analysis Shows Booz Allen Hamilton Holding, j2 Global, Leidos, The Hain Celestial Group, Palatin Technologies, and Marsh & McLennan Companies Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Booz Allen Hamilton Holding...

MMC : 83.00 (-1.23%)
JCOM : 70.78 (-1.13%)
BAH : 49.12 (-2.48%)
PTN : 0.72 (-1.37%)
LDOS : 57.05 (-2.38%)
HAIN : 18.45 (-3.91%)
Immunotherapy Market Value Grows as the Treatments Gains Widespread Importance

According to a report published by Progressive Markets, the cancer immunotherapy market was valued at USD 57.2 Billion in 2017 and is expected to reach USD 166.7 Billion by 2025 while growing at a compound...

AGEN : 2.42 (-3.20%)
RGBP : 0.0031 (-8.82%)
ZIOP : 2.84 (-2.41%)
PTN : 0.72 (-1.37%)
BLRX : 0.62 (-3.12%)
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2018 Results

Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic...

PTN : 0.72 (-1.37%)
AMAG : 16.80 (-1.12%)
Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year End 2018 Results; Teleconference and Webcast to be held on September 13, 2018

Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2018 operating results on Thursday, September 13, 2018 before the open of the U.S. financial markets....

PTN : 0.72 (-1.37%)
Global Biotechnology Market Grows as Demand for Immunotherapy Cancer Treatment Increases

Data compiled by Grand View Research indicates that the global biotechnology market is expected to reach USD 727.1 Billion by 2025. The technological advancement of regenerative therapies is one of the...

RGBP : 0.0031 (-8.82%)
ADMP : 2.81 (-2.77%)
NVAX : 2.41 (+4.78%)
PTN : 0.72 (-1.37%)
SGYP : 0.08 (-38.46%)
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on May 15, 2018

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need...

PTN : 0.72 (-1.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade PTN with:

Business Summary

Palatin Technologies, Inc is a development-stage medical technology companyinvolved in developing and commercializing products and technologies fordiagnostic imaging, cancer therapy and ethical drug development These developments are based on its proprietary monoclonal antibody radiolabeling and enabling...

See More

Key Turning Points

2nd Resistance Point 0.78
1st Resistance Point 0.75
Last Price 0.72
1st Support Level 0.70
2nd Support Level 0.68

See More

52-Week High 1.59
Fibonacci 61.8% 1.24
Fibonacci 50% 1.13
Fibonacci 38.2% 1.03
Last Price 0.72
52-Week Low 0.68

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar